CME Symposia Provided by Vindico Medical Education

 

Trending…Dosing, Anatomic Dryness, and Treatment Protocols in Retinal Diseases

  • Date: Friday, August 21, 2020
  • Time: 7:15pm – 8:15pm EDT

Faculty

Sophie J. Bakri, MD (Activity Chair)
Professor of Ophthalmology, Mayo Clinic (Rochester, MN)

Diana V. Do, MD
Vice Chair for Clinical Affairs
Professor of Ophthalmology, Stanford University School of Medicine, (Palo Alto, CA)
Byers Eye Institute

Overview: The incorporation of intravitreal therapy into treatment protocols for neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) have led to enhanced visual outcomes. In nAMD, anti–vascular endothelial growth factor (VEGF) therapies have demonstrated significant visual acuity gains yet lack of patient adherence due to treatment burden can result in suboptimal outcomes. Dosing strategies that elongate the time between injection intervals yet maintain early visual acuity gains are currently evolving. In patients with DR, early intervention with anti-VEGF therapies have demonstrated significant slowing of disease progression and reduction of vision-threatening complications. In this educational activity, experts in the field will review injection protocols that have been shown to improve the long-term management of DR and nAMD, as well as evaluate how the persistence of retinal fluid post-treatment may influence visual outcomes in patients with retinal diseases.

  • Credit Designation: Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
  • Supporter Statement: This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Exploring New Treatment Options in the Medical Management of Glaucoma

  • Date: Saturday, August 22, 2020
  • Time: 7:00PM – 8:00PM EDT

Faculty:

Oluwatosin U. Smith, MD (Activity Chair)
Attending Clinician and Surgeon
Associate Professor Ophthalmology, Department of Ophthalmology, UTSW Medical School
Glaucoma Associates of Texas (Dallas, TX)

Jody Piltz-Seymour, MD
Attending Surgeon, Wills Eye Hospital Glaucoma Service
Clinical Professor, Perelman School of Medicine, Dept of Ophthalmology, University of Pennsylvania
Valley Eye Professionals (Huntingdon Valley, PA)

Overview: Many patients with glaucoma are at risk for disease progression and potential impairment of vision-related quality of life due to inadequate control of intraocular pressure (IOP). Traditional glaucoma therapies target the aqueous humor production or aqueous outflow via the unconventional outflow pathway, but do little to restore function of the conventional outflow pathway. Recent advances have led to the development of novel classes of IOP-lowering therapies that alone or in combination have the potential to improve the medical management of glaucoma. In this educational activity, experts in the field will compare medical therapies with unique mechanisms of action and their incorporation into individualized treatment protocols, as well as review clinical studies evaluating the safety and efficacy of newer monotherapies and combination therapies for the management of glaucoma.

  • Credit Designation: Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
  • Supporter Statement: This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.

A Vision for the Future: Reducing the Burden of Anti-VEGF Therapy with Emerging Options

  • Date: Sunday, August 23
  • Time: 9:00 AM – 10:00 AM EDT

Faculty

Nancy M. Holekamp, MD (Activity Chair)
Pepose Vision Institute, Director of Retina Services
Professor of Clinical Ophthalmology, Washington University School of Medicine (St. Louis, MO)

Margaret Chang, MD, MS
Senior Partner, Retinal Consultants of Sacramento (Sacramento, CA)

Overview: Evolving advances for the treatment of neovascular retinal diseases have the potential to further enhance visual acuity outcomes while reducing treatment burden. Several novel delivery systems, along with therapies that target alternate pathways, are currently being evaluated in clinical studies. Understanding these therapeutic advances prior to their possible approval is imperative for their optimal integration into clinical practice. In this educational activity, experts in the field will review the burden associated with current treatment strategies in neovascular retinal diseases, investigate the role of subretinal fluid in determining response to treatment, as well as evaluate new and emerging modalities that may reduce the burden of anti-vascular endothelial growth factor (VEGF) therapy in neovascular retinal diseases.

  • Credit Designation: Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
  • Supporter Statement: This activity is supported by an educational grant from Genentech, Inc.